Third, despite some preliminary evidence for a role of the specific KRAS mutation (i.e., codon 12, 13, or 146) in tumor phenotype, the limited number of studies on this topic did not allow us to examine the association between specific mutation sites of the KRAS gene and treatment response. Here, KRAS is linked to neoplasm.